MONTASER, Ahmed B, Janita KUIRI, Teemu NATUNEN, Pavel HRUSKA, David POTĚŠIL, Seppo AURIOLA, Mikko HILTUNEN, Tetsuya TERASAKI, Marko LEHTONEN, Aaro JALKANEN and Kristiina M HUTTUNEN. Enhanced drug delivery by a prodrug approach effectively relieves neuroinflammation in mice. Life Sciences. Amsterdam: Elsevier, 2022, vol. 310, DEC, p. 121088-121099. ISSN 0024-3205. Available from: https://dx.doi.org/10.1016/j.lfs.2022.121088.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Enhanced drug delivery by a prodrug approach effectively relieves neuroinflammation in mice
Authors MONTASER, Ahmed B, Janita KUIRI, Teemu NATUNEN, Pavel HRUSKA, David POTĚŠIL (203 Czech Republic, guarantor, belonging to the institution), Seppo AURIOLA, Mikko HILTUNEN, Tetsuya TERASAKI, Marko LEHTONEN, Aaro JALKANEN and Kristiina M HUTTUNEN.
Edition Life Sciences, Amsterdam, Elsevier, 2022, 0024-3205.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30104 Pharmacology and pharmacy
Country of publisher United Kingdom of Great Britain and Northern Ireland
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 6.100
RIV identification code RIV/00216224:14740/22:00128511
Organization unit Central European Institute of Technology
Doi http://dx.doi.org/10.1016/j.lfs.2022.121088
UT WoS 000880317300008
Keywords in English Grid -hanging test; LAT1; LPS-induced neuroinflammation; Mouse brain proteome; Mouse membrane transporters; Rotarod
Tags CF PROT, rivok
Tags International impact, Reviewed
Changed by Changed by: Mgr. Pavla Foltynová, Ph.D., učo 106624. Changed: 2/2/2023 20:11.
Abstract
Aims: Neuroinflammation is a prominent hallmark in several neurodegenerative diseases (NDs). Halting neu-roinflammation can slow down the progression of NDs. Improving the efficacy of clinically available non -steroidal anti-inflammatory drugs (NSAIDs) is a promising approach that may lead to fast-track and effective disease-modifying therapies for NDs. Here, we aimed to utilize the L-type amino acid transporter 1 (LAT1) to improve the efficacy of salicylic acid as an example of an NSAID prodrug, for which brain uptake and intra-cellular localization have been reported earlier.Main methods: Firstly, we confirmed the improved LAT1 utilization of the salicylic acid prodrug (SA-AA) in freshly isolated primary mouse microglial cells. Secondly, we performed behavioural rotarod, open field, and four-limb hanging tests in mice, and a whole-brain proteome analysis.Key findings: The SA-AA prodrug alleviated the lipopolysaccharide (LPS)-induced inflammation in the rotarod and hanging tests. The proteome analysis indicated decreased neuroinflammation at the molecular level. We identified 399 proteins linked to neuroinflammation out of 7416 proteins detected in the mouse brain. Among them, Gps2, Vamp8, Slc6a3, Slc18a2, Slc5a7, Rgs9, Lrrc1, Ppp1r1b, Gnal, and Adcy5/6 were associated with the drug's effects. The SA-AA prodrug attenuated the LPS-induced neuroinflammation through the regulation of critical pathways of neuroinflammation such as the cellular response to stress and transmission across chemical synapses.Significance: The efficacy of NSAIDs can be improved via the utilization of LAT1 and repurposed for the treatment of neuroinflammation. This improved brain delivery and microglia localisation can be applied to other inflam-matory modulators to achieve effective and targeted CNS therapies.
Links
LM2018127, research and development projectName: Česká infrastruktura pro integrativní strukturní biologii (Acronym: CIISB)
Investor: Ministry of Education, Youth and Sports of the CR
LM2018140, research and development projectName: e-Infrastruktura CZ (Acronym: e-INFRA CZ)
Investor: Ministry of Education, Youth and Sports of the CR
PrintDisplayed: 14/5/2024 03:10